BOCA RATON, Fla., Feb. 28, 2019 /PRNewswire/ -- Sensus
Healthcare, Inc. (NASDAQ: SRTS), a medical device company
specializing in highly effective, non-invasive treatments for both
oncological and non-oncological conditions, announced today that
the Company has appointed Dr. Ziv
Karni to the role of Chief Scientific Officer, effective
immediately. Dr. Karni, a pioneer in medical technology research
and development, has more than 30 years of experience in the
development and sales of medical and aesthetic technologies. He
will report to Joe Sardano, Sensus
Healthcare CEO.
"As Dr. Karni has created some of the most successful
technologies that have been brought to market to date, he is a
strong addition to the Sensus leadership team and will be
instrumental in helping the Company to bring even more innovative,
life-changing technologies to patients across the globe," said
Sardano. "We look forward to working closely with Dr. Karni in the
near- and long-term and continuing to rapidly expand our product
portfolio across many different indications."
Dr. Karni joins Sensus from Alma Lasers, where he has served as
Founder, CEO, President and Head of Research and Development for
nearly two decades. Prior to forming Alma Lasers, he co-founded two
other laser-based companies, OrZiv and LBT. Most recently, Dr.
Karni established and serves as President of Zmed Laser, focusing
on laser-based solutions for the minimally invasive surgical
market. Overall, he holds more than 10 patents in the medical
device industry and has contributed to more than 50 published works
in the medical device field.
"As Sensus continues to make significant strides in the global
medical device industry with its highly effective, non-invasive
treatments, Dr. Karni's vast expertise in bringing new technologies
to market for patients in need all over the world will be
invaluable for our team," added Kal
Fishman, Sensus Healthcare Chief Technology Officer. "We are
eager to bring new innovative technologies as we expand our
footprint to new heights in 2019 and beyond."
About Sensus Healthcare
Sensus Healthcare, Inc., is a
medical device company that is committed to providing highly
effective, non-invasive and cost-effective treatments for both
oncological and non-oncological skin conditions. Sensus uses a
proprietary low-energy X-ray technology known as superficial
radiation therapy (SRT), which is a result of over a decade of
dedicated research and development. Sensus has successfully
incorporated SRT into its portfolio of treatment devices: the
SRT-100TM, SRT-100+TM and SRT-100
VisionTM. To date, SRT technology has been used to
effectively and safely treat oncological and non-oncological skin
conditions in thousands of patients around the world. With the
introduction of Sculptura™, Sensus Healthcare is branching out into
cancer treatment that goes far beyond skin and will provide a
revolutionary treatment option for patients around the world.
For more information,
visit https://www.sensushealthcare.com.
Forward-Looking Statements
This press release
includes statements that are, or may be deemed, ''forward-looking
statements.'' In some cases, these forward-looking statements can
be identified by the use of forward-looking terminology, including
the terms "believes," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should,"
"approximately," "potential" or, in each case, their negative or
other variations thereon or comparable terminology, although not
all forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive dynamics,
and healthcare, regulatory and scientific developments and depend
on the economic circumstances that may or may not occur in the
future or may occur on longer or shorter timelines than
anticipated. Although we believe that we have a reasonable basis
for each forward-looking statement contained in this press release,
we caution you that forward-looking statements are not guarantees
of future performance and that our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward
looking statements contained in this press release, as a result of,
among other factors: our ability to achieve and sustain
profitability; market acceptance of our product lines; our ability
to successfully commercialize our products; our ability to compete
effectively in selling our products and services, including
responding to technological change and cost containment efforts of
our customers; our need and ability to obtain additional financing
in the future, as well as complying with the restrictions our
existing revolving credit facility imposes; our ability to expand,
manage and maintain our direct sales and marketing organizations;
our actual financial results may vary significantly from forecasts
and from period to period; our ability to successfully develop new
products, improve or enhance existing products or acquire
complementary products, technologies, services or businesses; our
ability to obtain and maintain intellectual property of sufficient
scope to adequately protect our products, and our ability to avoid
infringing or otherwise violating the intellectual property rights
of third parties; market risks regarding consolidation in the
healthcare industry; the willingness of healthcare providers to
purchase our products if coverage, reimbursement and pricing from
third party payors for procedures using our products declines; the
level and availability of government and third party payor
reimbursement for clinical procedures using our products; our
ability to effectively manage our anticipated growth, including
hiring and retaining qualified personnel; the regulatory
requirements applicable to us and our competitors; our ability to
manufacture our products to meet demand; our reliance on third
party manufacturers and sole- or single-source suppliers; our
ability to reduce the per unit manufacturing costs; our ability to
efficiently manage our manufacturing processes; the regulatory and
legal risks, and certain operating risks, that our international
operations subject us to; off label use of our products; the fact
that product quality issues or product defects may harm our
business; the accuracy of our financial statements and accounting
estimates, including allowances for accounts receivable and
inventory obsolescence; any product liability claims; limited
trading in our shares and the concentration of ownership of our
shares; cyberattacks and other data breaches and the adverse effect
on our reputation; new legislation, administrative rules, or
executive orders, including those that impact taxes and
international trade regulation; the provisions in our certificate
of incorporation, bylaws, or Delaware law that discourage takeovers or that
limit certain disputes to be brought exclusively in the
Delaware Court of Chancery;
concentration of our customers in the U.S. and China, including the concentration of sales to
one particular customer in the U.S.; and other risks described from
time to time in Sensus Healthcare's filings with the Securities and
Exchange Commission, including the Company's Annual Report on Form
10-K.
In addition, even if our results of operations, financial
condition and liquidity, and the development of the industry in
which we operate are consistent with the forward-looking statements
contained in this press release, they may not be predictive of
results or developments in future periods. Any forward-looking
statements that we make in this press release speak only as of the
date of such statement, and we undertake no obligation to update
such statements to reflect events or circumstances after the date
of this press release. You should read carefully our "Cautionary
Note Regarding Forward-Looking Information" and the factors
described in the "Risk Factors" section of our periodic reports
filed with the Securities and Exchange Commission to better
understand the risks and uncertainties inherent in our
business.
Media Contacts:
Caitlin
Kasunich / Brittany
Tibaldi
KCSA Strategic Communications
212-896-1241 / 347-487-6794
ckasunich@kcsa.com / btibaldi@kcsa.com
Investor Contact:
Kim Sutton
Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sensus-healthcare-appoints-dr-ziv-karni-as-chief-scientific-officer-300804072.html
SOURCE Sensus Healthcare